A. Increased glucose-dependent insulin secretion from the pancreas B. Increased glucose-dependent glucagon secretion from the pancreas C. Increased urinary glucose output D. Increased peripheral glucose uptake in the muscle cells E. Unsure

A. They decrease A1C, weight, and blood pressure B. They decrease A1C, are weight neutral, and are inexpensive C. They decrease A1C and weight, and have a low risk of hypoglycemia D. They decrease A1C, have a low risk of hypoglycemia, and can be taken orally once weekly E. Unsure

A. Semaglutide B. Lixisenatide C. Liraglutide D. Dulaglutide E. Unsure

A. Liraglutide should be administered once daily at least 1 hour before breakfast. B. Liraglutide is available in a pre-filled, multi-use pen device; the patient must dial the pen to the desired dose. C. Dulaglutide should be administered once weekly at least 1 hour before breakfast on the same day each week. D. Dulaglutide is available in a pre-filled, multi-use pen device; the patient must dial the pen to the desired dose. E. Unsure

A. It may be a good alternative for a patient who experienced nausea with two other GLP-1 receptor agonists B. It may be a good alternative for a patient who has trouble using an injectable pen devise due to poor dexterity C. It may be a good alternative in patients with adherence issues who wish to take all their medications at once in the morning D. It may be a good alternative in patients with ASCVD because it lowers the risk of major CV events E. Unsure